Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (Nasdaq: EOLS) reported Q1 2021 net revenues of $12.2 million, a 16% increase from the previous year, aided by the resolution of an International Trade Commission (ITC) case. The company's pro forma cash position stood at $140 million as of March 31, 2021. The U.S. Jeuveau® business is on track for a $100 million annual revenue run rate in Q2 2021. Moreover, operating expenses decreased by 25.7% year-over-year, while gross margins are expected to stabilize post-September 2022.
Evolus, a performance beauty company, announced two Phase II peer-reviewed studies published in Aesthetic Surgery Journal showcasing the safety and efficacy of repeat doses of Jeuveau® for treating glabellar lines. Conducted to support regulatory approval in North America and Europe, the studies indicate prolonged use is safe, with decreasing adverse events noted over time. Jeuveau® employs patented Hi-Pure™ technology that minimizes antibody formation. The studies confirm the effectiveness of Jeuveau® as a viable neurotoxin alternative for consumers.
Evolus, a performance beauty company, will report its first quarter 2021 financial results on May 12, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, providing a business update and a Q&A session. Domestic callers can access the call at (866) 916-2317, while international callers should use (703) 925-2662, with conference ID 7749489. A replay will be available until May 19, 2021. The event can also be streamed live via the Evolus Investor Relations website.
Evolus, a performance beauty company, will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, from 3:30 PM to 4:10 PM ET. The event will feature a fireside chat and 1x1 meetings, allowing investors to engage with management. An audio webcast of the discussion will be accessible on the company's investor relations page and available for replay for 90 days post-event. Evolus is known for its aesthetic neurotoxin, Jeuveau®, approved by the FDA in 2019, and aims to transform the aesthetic market.
Evolus announced the pricing of a public offering of 9,000,000 shares of common stock at $9.50 each, aiming for gross proceeds of $85.5 million. The offering, expected to close around April 26, 2021, includes an option for underwriters to purchase an additional 1,350,000 shares. Proceeds will fund Jeuveau® growth in the U.S., European pre-launch activities, and general corporate purposes. The offering is managed by SVB Leerink, Stifel, and Cantor, with details available in the prospectus filed with the SEC.
Evolus, Inc. (Nasdaq: EOLS) has announced a proposed underwritten public offering of its common stock, subject to market conditions. The company may grant underwriters an option to purchase an additional 15% of shares. The net proceeds will fund the growth of Jeuveau® in the U.S., support European pre-launch activities, and cover general corporate purposes. This offering is managed by SVB Leerink, Stifel, and Cantor. Details are available in the preliminary prospectus supplement filed with the SEC.
Evolus, a performance beauty company, reported a strong Q4 2020 with net revenue of $20.6 million, its highest since launching Jeuveau®.
The company resolved significant litigation issues, eliminating $127 million in debt, and improved its cash position to $57 million as of December 31, 2020. Despite litigation expenses impacting operating results, gross margins were solid at 64.6% for Q4. The company expects net revenue to continue rising in 2021, despite short-term gross margin pressures due to settlement agreements.
Evolus, Inc. (NASDAQ: EOLS) will report its fourth quarter and year-end 2020 financial results on March 24, 2021. The company will hold a conference call at 4:30 p.m. ET to discuss these results and provide a business update. A question and answer session will follow management remarks. Domestic callers can dial (866) 916-2317, while international callers should use (703) 925-2662, with a conference ID of 7378855. A replay will be accessible until March 31, 2021. A live audio webcast will be available on the Evolus investor relations page and archived for 30 days.
Evolus, Inc. (Nasdaq: EOLS) announced a significant financial restructuring with Daewoong Pharmaceutical, enhancing its balance sheet. The settlement includes a $25.5 million cash payment, the elimination of $127.4 million in debt and milestone payments, and the conversion of $40.5 million in debt into approximately 3.1 million shares. This leaves Evolus with a pro forma cash position of $57 million as of December 31, 2020. The company aims to drive growth for its neurotoxin product Jeuveau® and expand internationally with the launch of Nuceiva™ in early 2022.
Evolus, a performance beauty company, announces participation in two virtual investor conferences. The first event is the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, featuring a fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference on March 10, 2021, with a presentation scheduled from 1:15 PM to 1:40 PM ET. Audio webcasts will be accessible on Evolus' investor relations website, with replays available for 90 days post-presentation.